Relapse · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab probably leads to lower number of participants experiencing ≥ 1 relapse compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
Number of participants with any serious adverse events · primary progressive multiple sclerosis
Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Number of adverse events requiring discontinuation of treatment ‐ not reported · primary progressive multiple sclerosis
Ocrelizumab showed no clear difference in number of participants experiencing treatment discontinuation caused… compared with placebo (low certainty).
1 finding from 1 review
Number of participants with gadolinium‐enhancing T1 lesions on MRI · primary progressive multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants with new or enlarging T2‐hyperintense lesions on MRI · primary progressive multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants experiencing disability progression · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab may leads to lower number of participants experiencing disability progression compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Number of participants with any adverse events · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab showed no clear difference in number of participants with any adverse events compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
Number of participants with any serious adverse events · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab may leads to lower number of participants experiencing treatment discontinuation caused… compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Number of participants with gadolinium‐enhancing T1 lesions on MRI · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab may leads to lower number of participants with gadolinium‐enhancing T1 lesions on MRI compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Number of participants with new or enlarging T2‐hyperintense lesions on MRI · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab may leads to lower number of participants with new or enlarging T2‐hyperintense lesions… compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Number of participants experiencing disability progression · primary progressive multiple sclerosis
Ocrelizumab may leads to lower number of participants experiencing disability progression compared with placebo (low certainty).
1 finding from 1 review
Number of participants with any adverse events · primary progressive multiple sclerosis
Ocrelizumab probably leads to higher number of participants with any adverse events compared with placebo (moderate certainty).
1 finding from 1 review